- Home
- HSII vs PVLA Comparison
HSII vs PVLA Comparison
Compare HSII & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSII | PVLA |
|---|---|---|
| Founded | 1953 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | HSII | PVLA |
|---|---|---|
| Price | $59.01 | $97.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 16 |
| Target Price | $57.50 | ★ $124.25 |
| AVG Volume (30 Days) | ★ 430.9K | 259.5K |
| Earning Date | 11-03-2025 | 11-11-2025 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.73 | N/A |
| Revenue | ★ $1,199,854,000.00 | N/A |
| Revenue This Year | $13.60 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.12 | ★ N/A |
| Revenue Growth | ★ 11.56 | N/A |
| 52 Week Low | $36.87 | $11.17 |
| 52 Week High | $59.05 | $106.71 |
Technical Indicators
Market Signals| Indicator | HSII | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 77.94 | 59.02 |
| Support Level | $58.84 | $95.28 |
| Resistance Level | $59.05 | $100.00 |
| Average True Range (ATR) | 0.09 | 6.07 |
| MACD | -0.11 | -0.60 |
| Stochastic Oscillator | 89.74 | 42.95 |
Price Performance
Historical ComparisonAbout HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments include the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.